Outputs (8)

A novel method to quantify fibrin–fibrin and fibrin–α2-antiplasmin cross-links in thrombi formed from human trauma patient plasma. (2024)
Journal Article
MORROW, G.B., FLANNERY, S., CHARLES, P.D., HEILIG, R., FELLER, T., MCQUILTEN, Z., WAKE, E., ARIENS, R.A.S., WINEARLS, J., MUTCH, N.J., FISCHER, R., LAFFAN, M.A. and CURRY, N. 2024. A novel method to quantify fibrin-fibrin and fibrin-α2-antiplasmin cross-links in thrombi formed from human trauma patient plasma. Journal of thrombosis and haemostasis [online], 22(6), pages 1758-1771. Available from: https://doi.org/10.1016/j.jtha.2024.03.001

The widespread use of the anti-fibrinolytic agent, tranexamic acid (TXA), interferes with the quantification of fibrinolysis by dynamic laboratory assays such as clot lysis, making it difficult to measure fibrinolysis in many trauma patients. At the... Read More about A novel method to quantify fibrin–fibrin and fibrin–α2-antiplasmin cross-links in thrombi formed from human trauma patient plasma..

Novel therapeutics and emerging technology in haemostasis and thrombosis: highlights from the British Society for Haemostasis and Thrombosis annual meeting. (2023)
Journal Article
WHYTE, C.S., MORROW, G.B., GAUER, J.S., MONTAGUE, S.J. and NICOLSON, P.L.R. 2023. Novel therapeutics and emerging technology in haemostasis and thrombosis: highlights from the British Society for Haemostasis and Thrombosis annual meeting (BSHT2023), 25-27 January 2023, Birmingham, UK. Front in cardiovascular medicine [online], 10, article number 1225243. Available from: https://doi.org/10.3389/fcvm.2023.1225243

The BSHT held its annual meeting between January 25th and 27th 2023 at the Edgbaston Park Hotel & Conference Centre, Birmingham, United Kingdom. The meeting is an opportunity for academic researchers, biomedical scientists and clinicians to network a... Read More about Novel therapeutics and emerging technology in haemostasis and thrombosis: highlights from the British Society for Haemostasis and Thrombosis annual meeting..

Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). (2022)
Journal Article
MORROW, G.B. and MUTCH, N.J. 2023. Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Seminars in thrombosis and hemostasis [online], 49(3), pages 305-313. Available from: https://doi.org/10.1055/s-0042-1758791

Plasminogen activator inhibitor 1 (PAI-1), a SERPIN inhibitor, is primarily known for its regulation of fibrinolysis. However, it is now known that this inhibitor functions and contributes to many (patho)physiological processes including inflammation... Read More about Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1)..

The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. (2022)
Journal Article
WHYTE, C.S., SIMPSON, M., MORROW, G.B., WALLACE, C.A., MENTZER, A.J., KNIGHT, J.C., SHAPIRO, S., CURRY, N., BAGOT, C.N., WATSON, H., COOPER, J.G. and MUTCH, N.J. 2022. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. Journal of thrombosis and haemostasis [online], 20(10), pages 2394-2406. Available from: https://doi.org/10.1111/jth.15806

Severe COVID-19 disease is associated with thrombotic complications and extensive fibrin deposition. This study investigates whether the hemostatic complications in COVID-19 disease arise due to dysregulation of the fibrinolytic system. This prospect... Read More about The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1..

Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: results from a laboratory sub-study of the FEISTY trial. (2022)
Journal Article
MORROW, G.B., FELLER, T., MCQUILTEN, Z., WAKE, E., ARIËNS, R.A.S., WINEARLS, J., MUTCH, N.J., LAFFAN, M.A. and CURRY, N. 2022. Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: results from a laboratory sub-study of the FEISTY trial. Critical care [online], 26, article number 290. Available from: https://doi.org/10.1186/s13054-022-04167-x

Fibrinogen is the first coagulation protein to reach critical levels during traumatic haemorrhage. This laboratory study compares paired plasma samples pre- and post-fibrinogen replacement from the Fibrinogen Early In Severe Trauma studY (FEISTY; NCT... Read More about Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: results from a laboratory sub-study of the FEISTY trial..

Removing plasmin from the equation: something to chew on… (2022)
Journal Article
MORROW, G.B. and MUTCH, N.J. 2022. Removing plasmin from the equation: something to chew on… Journal of thrombosis and haemostasis [online], 20(2), pages 280-284. Available from: https://doi.org/10.1111/jth.15590

Thrombolytics or fibrinolytics are a group of pharmacological agents used to target and dissolve occlusive intravascular thrombi. Thrombi form a haemostatic plug at the site of injury to arrest bleeding and are essential for wound healing. However, i... Read More about Removing plasmin from the equation: something to chew on….

Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. (2020)
Journal Article
WHYTE, C.S., MORROW, G.B., MITCHELL, J.L., CHOWDARY, P. and MUTCH, N.J. 2020. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. Journal of thrombosis and haemostasis [online], 18(7), pages 1548-1555. Available from: https://doi.org/10.1111/jth.14872

The global pandemic of coronavirus disease 2019 (COVID‐19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflamm... Read More about Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19..

Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyzer. (2020)
Journal Article
MORROW, G.B., BEAVIS, J., HARPER, S., BAKER, P., DESBOROUGH, M.J.R., CURRY, N., STANWORTH, S.J. and LAFFAN, M.A. 2020. Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyzer. Journal of thrombosis and haemostasis [online], 18(7), pages 1576-1585. Available from: https://doi.org/10.1111/jth.14802

The liver synthesizes the majority of pro- and anti-oagulant and fibrinolytic proteins, and during liver dysfunction synthesis of these proteins is reduced. The end point of conventional hemostatic tests, such as the prothrombin time (PT), occurs whe... Read More about Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyzer..